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Purpose
The impact of postoperative ipsilateral neck radiotherapy (INRT) versus bilateral neck 
radiotherapy (BNRT) on the clinical outcomes of patients with tonsillar squamous cell car-
cinoma was analyzed retrospectively. 
Materials and Methods
Between October 2001 and June 2012, 241 patients with T1-2 and N0-N2b tonsillar carci-
noma from 16 institutes underwent postoperative INRT (n=84) or BNRT (n=157) following a
tonsillectomy. Seventy patients were identified from each group by propensity score matching
and compared in terms of the overall survival (OS), disease-free survival (DFS), locoregional
relapse-free survival (LRRFS), and distant metastasis-free survival (DMFS) rates calculated
using the Kaplan-Meier method with a log-rank test.
Results
The median follow-up was 55 months (range, 3 to 133 months). The survival outcomes in
the INRT and BNRT groups were similar: 5-year OS (92.8% vs. 94.0%, p=0.985), DFS (80.5%
vs. 94.2%. p=0.085), LRRFS (88.1% vs. 97.1%, p=0.083), and DMFS (92.7% vs. 97.0%,
p=0.370). Subgroup analysis revealed no contralateral neck recurrence in 61 patients with
T1-2N0-2a regardless of the treatment groups. For 79 patients with N2b, contralateral neck
recurrence was more common in the INRT group than in the BNRT group (7.9% vs. 0.0%),
but the difference was not significant (p=0.107). The overall grade  2 toxicities were lower
in the INRT group: acute (45.7% vs. 74.3%, p=0.001) and late (4.3% vs. 31.4%, p < 0.001),
respectively.
Conclusion
INRT is an attractive strategy for patients with T1-2N0-2a tonsillar carcinoma compared to
BNRT. For patients with N2b, there was a small risk of contralateral neck recurrence when
treated with INRT, but its impact on the OS was limited with successful salvage treatment.
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Introduction
In carcinoma of the oropharyngeal region, the area treated
with radiation conventionally includes both cervical lym-
phatic chains, regardless of nodal involvement, because
metastasis to the regional lymph nodes is reported fre-
quently, even in clinically node-negative tumors [1,2]. This
extensive radiation-targeted volume contributes to favorable
locoregional control in tonsil cancer but it may also lead to
treatment-related morbidity, such as xerostomia, dysphagia,
and mucositis. Permanent xerostomia is one of the most com-
mon and distressing complications after radiation treatment
for head and neck cancer. Intensity-modulated radiotherapy
(IMRT) is a good strategy for preventing xerostomia because
the salivary glands can be spared [3]. Although IMRT 
reduces long-term severe xerostomia compared to three-
dimensional conformal radiotherapy (3D-CRT), other seque-
lae, including the skin and mucosal toxicity, as well as low
grade xerostomia can persist after IMRT [4,5]. In addition,
patients treated unilaterally achieve faster recovery and
higher salivary function relative to the pretreatment levels
than those treated bilaterally by IMRT [5,6].
Several institutes have reported their experience of using
a limited radiation field for patients with well-lateralized
cancers of the tonsillar fossa to exclude treating the unin-
volved contralateral neck; the contralateral regional recur-
rence rates were < 6% [7-11]. These findings suggest that not
all patients are likely to benefit from prophylactic radiation
encompassing the contralateral neck. Recently, there is an 
increasing trend of younger patients with oropharyngeal
cancer usually associated with the human papillomavirus
(HPV) [12]. The treatment outcomes for HPV-related oropha-
ryngeal cancer are superior to those of non-HPV–related dis-
ease [13,14]. These evolving trends could also support a
de-intensification strategy through a reduction of the radia-
tion volume. Although the American College of Radiology
provided recommendations for ipsilateral neck radiotherapy
(INRT) based on published retrospective data, there are no
reports comparing the survival outcomes and failure pat-
terns between INRT and bilateral neck radiotherapy (BNRT). 
This study analyzed retrospectively the clinical outcomes
based on the radiotherapy (RT) area, for INRT versus BNRT,
in patients who underwent a tonsillectomy for the treatment
of tonsillar cancer who were matched using a propensity-
scoring method. The investigation was a multi-institutional,




The medical records of patients with tonsillar carcinoma,
who received a tonsillectomy followed by adjuvant RT 
between October 2001 and June 2012 at 16 institutes in Korea,
were reviewed retrospectively. The eligibility criteria for the
present study included (1) histologically confirmed squa-
mous cell carcinoma in the tonsillar region, (2) non-distant
metastatic disease status at diagnosis, (3) postoperative treat-
ment with 3D-CRT or IMRT, (4) age  20 years, (5) Eastern
Cooperative Oncology Group (ECOG) performance status 
0-2, and (6) no previous radiation of the head and neck 
region. Of 390 patients, 149 were excluded from the analyses
for the following reasons: advanced disease, which is classi-
fied as T3-4 or N3 (n=88); bilateral neck lymph nodes 
involvement (n=37); incomplete treatment (n=2); and insuf-
ficient data for analysis (n=22). Ultimately, 241 patients were
included in the analysis. 
Of these 241 patients, seventy patients were identified
from each group (INRT and BNRT) by propensity score
matching (PSM) based on their smoking history, chemother-
apy, extranodal extension, T/N classification, and perform-
ance status. After PSM, the patients in each group were
comparable in terms of the potential prognostic indicators.
Table 1 lists the patient characteristics before and after PSM.
All patients underwent pretreatment workup comprising a
physical examination, routine laboratory testing (complete
blood count, liver function test), chest radiography, and neck
magnetic resonance imaging or computed tomography. 18F-
deoxyfluoroglucose positron emission tomography–com-
puted tomography and neck ultrasonography were also
applied when necessary. 
2. Treatments
The extent and radiation dose were determined by the
policies of each institution. The clinical target volume (CTV)
was defined as follows: CTV1, primary tumor bed and the
neck level of involved nodes; CTV2, adjacent neck level of
involved nodes; and CTV3, elective region of the uninvolved
neck. The planning target volume (PTV) was defined as the
CTV plus 0.3-1.0 cm in all directions. For INRT, the median
total doses applied to PTV1, PTV2, and PTV3 were 60.0 Gy
(range, 54.0 to 70.0 Gy), 59.4 Gy (range, 36.0 to 70.0 Gy), and
45.0 Gy (range, 36.0 to 54.0 Gy), respectively, with a daily
dose of 1.71 to 2.25 Gy. For BNRT, the median total doses 
applied to PTV1, PTV2, and PTV3 were 63.0 Gy (range, 50.0
to 72.0 Gy), 54.0 Gy (range, 27.0 to 66.0 Gy), and 50.0 Gy
(range, 30.6 to 60.0 Gy), respectively, with a daily dose of 1.6-
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Total population Propensity score-matched population
Characteristic
INRT (n=84) BNRT (n=157) p-valuea) INRT (n=70) BNRT (n=70) p-valuea)
Age (yr)
Median (range) 54 (31-76) 54 (32-81) 55 (31-76) 55 (32-81)
< 60 58 (69.0) 113 (72.0) 0.633 48 (68.6) 50 (71.4) 0.712 
 60 26 (31.0) 44 (28.0) 22 (31.4) 20 (28.6)
Sex
Male 73 (86.9) 141 (89.8) 0.496 61 (87.1) 62 (88.6) 0.796 
Female 11 (13.1) 16 (10.2) 9 (12.9) 8 (11.4)
Histologic grade
WD 14 (16.7) 17 (10.8) 0.087 9 (12.9) 5 (7.1) 0.348 
MD 45 (53.6) 96 (61.1) 39 (55.7) 45 (64.3)
PD 17 (20.2) 39 (24.8) 15 (21.4) 17 (24.3)
NA 8 (9.5) 5 (3.2) 7 (10.0) 3 (4.3)
HPV
(+) 5 (6.0) 11 (7.0) 0.526 4 (5.7) 5 (7.1) 0.807 
(–) 3 (3.6) 2 (1.3) 3 (4.3) 1 (1.4)
NA 76 (90.5) 144 (91.7) 63 (90.0) 64 (91.4)
Smoking
Never smoking 44 (52.4) 56 (35.7) 0.010* 36 (51.4) 33 (47.1) 0.536 
Yes, but quit 19 (22.6) 27 (17.2) 13 (18.6) 18 (25.7)
Current smoker 16 (19.0) 59 (37.6) 16 (22.9) 17 (24.3)
NA 5 (6.0) 15 (9.6) 5 (7.1) 2 (2.9)
Extracapsular extension
(+) 22 (26.2) 48 (30.6) 0.766 22 (48.6) 18 (25.7) 0.594 
(–) 46 (54.8) 82 (52.2) 34 (31.4) 40 (57.1)
NA 16 (19.0) 27 (17.2) 14 (20.0) 12 (17.1)
T classification
1 29 (34.5) 55 (35.0) 0.937 23 (32.9) 25 (35.7) 0.722 
2 55 (65.5) 102 (65.0) 47 (67.1) 45 (64.3)
N classification
0 20 (23.8) 14 (8.9) < 0.001* 10 (14.3) 10 (14.3) 0.953 
1 20 (23.8) 20 (12.7) 16 (22.9) 14 (20.0)
2a 6 (7.1) 11 (7.0) 6 (8.6) 5 (7.1)
2b 38 (45.2) 112 (71.3) 38 (54.3) 41 (58.6)
Staging
I 5 (6.0) 1 (0.6) < 0.001* 3 (4.3) 1 (1.4) 0.751 
II 15 (17.9) 13 (8.3) 7 (10.0) 9 (12.9)
III 20 (23.8) 20 (12.7) 16 (22.9) 14 (20.0)
IVA 44 (52.4) 123 (78.3) 44 (62.9) 46 (65.7)
Chemotherapy
Yes 18 (21.4) 50 (31.8) 0.029* 17 (24.3) 18 (25.7) 0.845 
No 66 (78.6) 107 (68.2) 53 (75.7) 52 (74.3)
ECOG PS
0 18 (21.4) 60 (38.2) 0.002* 18 (25.7) 15 (21.4) 0.803 
1 64 (76.2) 83 (52.9) 50 (71.4) 52 (74.3)
2 0 ( 6 (3.8) 0 ( 0 (
NA 2 (2.4) 8 (5.1) 2 (2.9) 3 (4.3)
Table 1. Patients’ characteristics before and after propensity-score matching
Values are presented as number (%). INRT, ipsilateral neck radiotherapy; BNRT, bilateral neck radiotherapy; WD, well differ-
entiated; MD, moderately differentiated; PD, poorly differentiated; NA, not available; HPV, human papillomavirus; ECOG, East-
ern Cooperative Oncology Group; PS, performance status. *Statistical significance (p < 0.05). a)Chi-square or Fisher exact test. 
2.4 Gy. More patients in the BNRT group received IMRT than
in the INRT group (31/70, 44.2% vs. 5/70, 7.1%, respec-
tively). A neck dissection was performed in 59 (84.3%) and
55 (78.6%) patients in the INRT and BNRT groups, respec-
tively. Chemotherapy was administered sequentially or con-
currently with regimens, including cisplatin, carboplatin, or
cetuximab. 
3. Statistical analysis 
The patients were allocated to either the INRT or BNRT
group based on whether or not the radiation volume encom-
passed the uninvolved contralateral neck. The baseline char-
acteristics of the patients were compared using chi-sqaure or
Fisher exact tests. PSM was conducted by modeling the prob-
ability of the patients in both the INRT and BNRT groups.
The probability of each individual patient was estimated
using a logistic regression model based on their smoking his-
tory, administration of chemotherapy, extranodal extension,
T/N classification, and ECOG performance status. The
events of locoregional recurrence-free survival (LRRFS), dis-
tant metastasis-free survival (DMFS), disease-free survival
(DFS), and overall survival (OS) were defined as locoregional
recurrence, distant metastasis, any recurrence or death, and
Cancer Res Treat. 2017;49(4):1097-1105
Fig. 1. Comparison of the 5-year overall survival (OS) (A), disease-free survival (DFS) (B), locoregional relapse-free survival
(LRRFS) (C), and distant metastasis-free survival (DMFS) (D) rates between the ipsilateral neck radiotherapy (INRT) and 
































































































DMFS 92.7% vs. 97.0%, p=0.370
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death, respectively. The survival rates were calculated from
the initial date of treatment (tonsillectomy) to the date of each
event or the last follow-up and were compared using the 
Kaplan-Meier method and log-rank test. The treatment-
related toxicities were graded using the Radiation Therapy
Oncology Group acute and late morbidity scoring system
[15]. Acute toxicity was defined as occurring within 90 days
of the initiation of treatment with toxicity considered late.
The rates of toxicities in the two groups were compared
using chi-square or Fisher exact tests. In all tests, p-values of
< 0.05 were considered significant.
Results
1. Survival and patterns of failure 
The median follow-up duration of the PSM population
was 55 months (range, 3 to 133 months). The 5-year LRRFS
(88.1% vs. 97.1%, p=0.083) and DFS (80.5% vs. 94.2%,
p=0.085) rates were higher in the BNRT group than in the
INRT group with borderline significance. No significant dif-
ferences in the DMFS (92.7% vs. 97.0%, p=0.370) and OS
(92.8% vs. 94.0%, p=0.985) were observed (Fig. 1). Fig. 2 pres-
ents the patterns of failure. A total of 11 patients (15.7%) in
the INRT group experienced recurrence, whereas only three
patients (4.3%) experienced recurrence in the BNRT group.
In the INRT group, three (4.3%) and one (1.4%) patient had
isolated local and regional recurrence, respectively, three
(4.3%) had locoregional recurrence, and four (5.7%) experi-
enced distant recurrence. In the BNRT group, one patient
each experienced local, distant, and regional with distant 
recurrences. Three patients (4.3%) and no patients had con-
tralateral regional recurrence in the INRT and BNRT group,
respectively, but the difference between the groups was not
statistically significant (p=0.245). The three patients in the
INRT group with contralateral regional recurrence included
one with an isolated regional recurrence and two with 
regional combined with local recurrence.
In subgroup analysis, there were no contralateral neck 
recurrences in patients with T1-2N0-2a regardless of the
treatment groups, INRT or BNRT. For patients with N2b,
contralateral neck recurrence was more common in the INRT
group than in the BNRT group (3/38 patients [7.9%] vs. 0/41
patients [0.0%], respectively), but the difference was not sta-
tistically significant (p=0.107). There was also a difference in
the 5-year LRRFS (84.8% vs. 94.3%, p=0.234), but no statistical
significance was identified. The 5-year OS (92.0% vs. 89.6%,
p=0.750) was similar in the two groups after salvage treat-
ment. 
Youngkyong Kim, Ipsilateral Versus Bilateral Neck RT in Tonsil Cancer
Fig. 2. Patterns of failure in the ipsilateral neck radiotherapy (INRT) and bilateral neck radiotherapy (BNRT) groups defined
by propensity-score matching. a)Including two contralateral regional faliure, b)Including one contralateral regional faliure.
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2. Toxicities
Table 2 compares the acute and late toxicities occurring in
patients in the INRT and BNRT groups. A statistically signif-
icant difference in the occurrence of grade  2 acute toxicities
was observed between the INRT and BNRT groups (45.7%
vs. 74.3%, p=0.001). Xerostomia was observed three times
more frequently in the BNRT group than in the INRT group
(38.6% vs. 12.9%, p=0.001), and severe oral mucositis (grade
3) was observed in 7.1% and 18.6% of patients in the INRT
and BNRT groups, respectively (p=0.043). Among the late
toxicities, 20 patients (28.6%) in the BNRT group suffered
Cancer Res Treat. 2017;49(4):1097-1105
Table 2. Acute and late toxicities of the patients treated with INRT and BNRT
Toxicity Gradea) INRT (n=70) BNRT (n=70) p-valueb)
Acute
Xerostomia 0 32 (45.7) 11 (15.7) < 0.001*
1 29 (41.4) 32 (45.7)
2 8 (11.4) 25 (35.7)
3 1 (1.4) 2 (2.9)
Oral mucositis 0 10 (14.3) 7 (10.0) 0.015* 
1 32 (45.7) 17 (24.3)
2 23 (32.9) 33 (47.1)
3 5 (7.1) 13 (18.6)
Late
Xerostomia 0 38 (54.3) 19 (27.1) < 0.001*
1 29 (41.4) 31 (44.3)
2 3 (4.3) 18 (25.7)
3 0 ( 2 (2.9)
Dysphagia 61 (87.1) 49 (70.0) 0.008*
1 9 (12.9) 15 (21.4)
2 0 ( 6 (8.6)
Values are presented as number (%). INRT, ipsilateral neck radiotherapy; BNRT, bilateral neck radiotherapy. *Statistical sig-
nificance (p < 0.05). a)Radiation Therapy Oncology Group acute and late morbidity scoring criteria, b)Chi-square or Fisher exact
test. 
No Sex/Age Stage CCRT RTa) Total Location of recurrence Time to Treatment for Last (yr) dose (Gy) recurrence (mo) recurrence status
1 M/52 cT2N0 N INRT 64.8 Local 7 None NA
2 M/54 cT2N2b N BNRT 60.0 Local 3 Surgery CR
3 M/65 cT2N2a N INRT 66.0 Local 27 Surgery CR
4 M/51 cT2N2b Y INRT 60.0 Local 6 Surgery CR
5 M/51 cT2N2b Y INRT 60.0 Local+regional (contralateral) 20 OP+reRT+CT CR
6 M/47 cT2N2b N INRT 63.0 Local+regional (ipsilateral) 5 CT PD
7 M/78 cT1N2b N BNRT 63.0 Regional (ipsilateral)+distant 12 CT PD
8 M/53 cT2N2b Y INRT 63.0 Local+regional (bilateral) 51 None NA
9 M/67 cT2N2b N INRT 54.0 Regional (contralateral) 22 Surgery CR
Table 3. Salvage treatment in patients with a locoregional recurrence (n=9)
CCRT, concurrent chemoradiation; RT, radiotherapy; N, no; INRT, ipsilateral neck radiotherapy; NA, not available; BNRT,
bilateral neck radiotherapy; CR, complete response; Y, yes; OP, operation; reRT, re-radiotherapy; CT, chemotherapy; PD, pro-
gressive disease. a)All patients with locoregional recurrence were treated by three-dimensional conformal radiotherapy.
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persistent xerostomia, compared to only three (4.3%) in the
INRT group. No grade 3 toxicity was observed in either
group, but six patients (8.6%) in the BNRT group experi-
enced grade 2 dysphagia. The overall incidence of grade  2
late toxicities were 7.1% in INRT and 18.6% in BNRT (p <
0.001).   
3. Salvage treatment after locoregional recurrence 
Nine patients experienced locoregional recurrence; five of
them were salvaged successfully with surgery or combined
treatment (Table 3). Two patients died of progressive disease,
despite chemotherapy. No information on the treatment after
recurrence was available for the remaining two patients 
because they were loss to follow-up. 
Discussion
Although current consensus recommendations [16] sug-
gested bilateral prophylactic neck irradiation for N2b or
more advanced disease, the data from a cohort of patients, 
> 50% of whom had N2b disease, showed that INRT pro-
vides favorable outcomes with less RT-related toxicity in 
patients with tonsillar carcinoma. In this study, the 5-year
LRRFS of patients receiving INRT was 88.1%, and contralat-
eral neck recurrence was 4.3%. These results are similar to
those reported in previous studies using INRT for the treat-
ment of cancer of the tonsillar region [7-11]. As one of the
largest series evaluating INRT for sparing the uninvolved
contralateral neck, O’Sullivan et al. [11] reported that INRT
resulted in a 3-year local control rate of 77% and 3.5% con-
tralateral regional recurrence in 228 patients with carcinoma
of the tonsillar region. In their study, six out of eight patients,
whose primary lesion involved the palate or base of the
tongue, showed contralateral neck failure, and they sug-
gested that disease confined to the mucosa and with no more
than 1 cm of medial extension could be treated safely by
INRT. Since that report, several studies have supported
INRT as an effective approach in selected patients without
N3 disease. Chronowski et al. [8] reported excellent out-
comes of INRT in a limited number of patients (n=102) with
TX-2 and NX-2b with low rates of contralateral neck nodal
relapse (2%) and perfect locoregional control (5-year rate
100%). Other studies including T3 disease also suggested 
favorable outcomes, and reported contralateral recurrence
rates of 1%-6% and 5-year locoregional control of 90%-94%
[7,10]. 
Our data indicated a borderline significant difference in
LRRFS between the INRT and BNRT groups in the PSM pop-
ulation (88.1% vs. 97.1%, p=0.083). In the BNRT group, local-
regional recurrence occurred in two patients (one local and
one regional and distant). In the INRT group, local-regional
recurrence occurred in seven patients (three local, three local-
regional, and one isolated contralateral). Of these six patients
with local recurrence, two patients showed out-of-field local
failure and the remaining four patients had in-field failure.
The difference in LRRFS may be due to the difference in 
radiation modality, in which only five patients (7%) in the
INRT group were treated with IMRT compared to 31 patients
(44%) in the BNRT group. Delivering a homogeneous radia-
tion dose to the target volumes including the cervical lym-
phatic area by 3D-CRT is an inherent challenge. McBride et
al. [17] reported that better local control can be achieved
using IMRT for the treatment of oropharyngeal cancer. They
revealed a lower locoregional failure rate for IMRT com-
pared to conventional RT (1.3% vs. 10.7%, p=0.017). The
other advantage of IMRT includes its ability to deliver a
higher dose to the target volume with a limited dose to the
normal organs. In this study, the median prescribed dose in
eight patients with locoregional recurrence (excluding one
isolated contralateral regional recurrence among total nine 
patients) was 63 Gy (range, 60 to 66 Gy), which was similar
to the 63 Gy (range, 50 to 72 Gy) in the BNRT group. The 
median PTV doses of four patients with in-field local failure
in the INRT group were 60.0, 63.0, 63.0, and 64.8 Gy, respec-
tively. Therefore, a higher local failure rate in the INRT group
might have been related to other factors, such as the inho-
mogeneous dose distribution, rather than the prescription
dose. Considering that the major pattern of failure was local
recurrence in the INRT group, where 3D-CRT were used in
the majority of patients, the wider adoption of IMRT in 
recent years may improve local control in patients treated
with INRT.
The RT modality (3D-CRT vs. IMRT) could have been used
as a variable for PSM to minimize bias. On the other hand,
3D-CRT was covered by the National Health Insurance in
Korea during the period of this study, whereas IMRT was
not. Therefore, 3D-CRT was used more often in relatively
simple INRT, whereas IMRT was used more frequently for
BNRT. Hence, there might be a discrepancy in the socio-eco-
nomic status between the two groups, which could affect the
clinical outcome. Considering that all potential unfavorable
compounding factors were potentially more prevalent in the
INRT group, the 5-year OS rate in this group was not inferior
to that in the BNRT group (92.8% vs. 94.0%, p=0.985). This is
partly due to the successful salvage treatment; of five 
patients receiving salvage treatment after locoregional recur-
rence in the INRT group, four (80%) achieved a complete 
response.  
Subgroup analysis of the patients with N2b revealed con-
siderable differences in the 5-year LRRFS (84.8% vs. 94.3%,
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p=0.234) and contralateral neck recurrence (7.9% vs. 0.0%,
p=0.107) between the INRT and BNRT groups. If the analy-
ses were performed with a larger cohort, it might have
reached statistical significance. On the other hand, the risks
of contralateral neck recurrence are still small (7.9%) with
only one patient with an isolated contralateral neck, which
was salvaged successfully by a surgical resection. Therefore,
INRT for patients with N2b can still be offered cautiously for
patients who are fit for BNRT.
A HPV infection is associated with favorable outcomes 
(locoregional control and survival) [13]. Unfortunately, 
information on the HPV infection status was limited to a
small subset of patients in the present study (21/241, 9%);
hence, the importance of HPV as a prognostic factor could
not be assessed. In addition, the smoking history is an 
important prognostic indicator. The data contained a similar
distribution of non-smokers between the both groups (INRT
51.4% vs. BNRT 47.1%, p=0.536).
Significant differences in the toxicities during or after RT
were observed between the INRT and BNRT groups. The 
patients in the BNRT group were more likely to have persist-
ent xerostomia and dysphagia compared to those in the
INRT group, even though more patients in the BNRT group
were treated with IMRT (INRT 7.1% vs. BNRT 44.2%). Only
three patients (4%) in the INRT group experienced grade  2
xerostomia, whereas 20 patients (29%) in the BNRT group
experienced this problem. Moreover, approximately 10% of
patients receiving BNRT experienced grade 2 dysphagia,
whereas none of the patients undergoing INRT did. The 3%
rate of xerostomia in this population was modestly superior
to that of the 8% reported by Dan et al. [18] who published
the outcomes of INRT for node-positive tonsil cancer with a
median follow-up of 37.2 months. IMRT is an advantageous
option to reduce xerostomia when treating head and neck
cancer because it facilitates the delivery of lower radiation
doses to the parotid gland. Vergeer et al. [3] compared IMRT
with 3D-CRT with regard to xerostomia in head and neck
squamous cell carcinoma and reported that the mean dose
to the parotid glands was reduced significantly (27 Gy vs. 43
Gy, p < 0.001). Grade 2 xerostomia was observed less fre-
quently in patients treated with IMRT than 3D-CRT (32% vs.
56%, p=0.002). The xerostomia rate of 32% after IMRT treat-
ment was consistent with our finding of 29% in the BNRT
group; however, it was considerably worse than the 4% of
the patients observed in the INRT group. Jellema et al. [6],
who evaluated RT-induced xerostomia by comparing INRT
with BNRT in head and neck cancer, reported that the sali-
vary function could be recovered to the baseline level by
sparing the contralateral neck, being compensated for by 
hyperfunction of the contralateral parotid. Considering the
findings from previous studies, exclusion of the uninvolved
contralateral neck from the target volume is a more favorable
strategy for maintaining the salivary function after treatment,
even though the IMRT was adopted widely for the treatment
of head and neck cancer.  
The limitations of this study are related to its retrospective
nature. INRT was compared with BNRT in terms of the 
locoregional control and survival in a population adjusted
by PSM. Although the heterogeneous distribution of the clin-
ical parameters that could influence the prognosis of patients
was balanced after PSM, unknown confounding factors, such
as physician selection bias regarding which patients received
INRT, could remain. 
In conclusion, given the data suggesting comparable out-
comes with less toxicity, INRT is an attractive strategy in 
T1-2N0-2a patients with tonsillar carcinoma, compared to
BNRT. For patients with N2b, there were small risks of con-
tralateral neck recurrence when treated with INRT, but its
impact on OS was limited with successful salvage treatment.
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